
You are here
Scheduling delegate's interim decisions and invitation for further comment: ACCS/ACMS, July 2016
Print version
Scheduling medicines and poisons
Summary
Part A - Interim decisions on scheduling proposals referred to an advisory committee (July 2016)
1. Advisory Committee on Medicines Scheduling (ACMS#18)
Substance | Interim decision |
---|---|
Ulipristal |
Schedule 4 - Amend EntryULIPRISTAL except when included in Schedule 3. Schedule 3 - New EntryULIPRISTAL for emergency post-coital contraception. Proposed implementation date: 1 February 2017 |
Fexofenadine |
Schedule 4 - Amend EntryFEXOFENADINE except:
Schedule 2 - Amend EntryFEXOFENADINE in preparations for oral use except in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:
Proposed implementation date: 1 February 2017 |
2,4-Dinitrophenol |
Schedule 10 - New Entry2,4-DINITROPHENOL for human use. Schedule 7 - Amend EntryDINITROPHENOLS except when included in Schedule 4, 6 or 10. Proposed implementation date: 1 February 2017 |
N,N-Dimethyltryptamine |
The current scheduling remains appropriate for N,N-dimethyltryptamine. |
Piper methysticum (kava) |
The current scheduling remains appropriate for piper methysticum (kava). |